Author Interviews, Cancer Research, Genetic Research, JAMA / 24.03.2017
Based on Genetic Profile, Longer Adjuvant Treatment Recommended for Some GIST Tumors
MedicalResearch.com Interview with:
Heikki Joensuu, MD
Department of Oncology
Helsinki University Hospital
University of Helsinki
Helsinki, Finland
MedicalResearch.com: What is the background for this study?
Response: The randomized Scandinavian Sarcoma Group (SSG) XVIII trial compared three years of adjuvant imatinib to one year of adjuvant imatinib as adjuvant treatments of patients who had undergone macroscopically complete surgery for a GIST with a high risk for tumor recurrence. In this trial, patients treated with 3 years of imatinib had improved overall survival as compared to those who were allocated to one year of adjuvant imatinib. In 2 other randomized trials that compared either 1 year of adjuvant imatinib to one year or placebo, or 2 years of adjuvant imatinib to observation, no improvement in overall survival was found, although in all three trials adjuvant imatinib improved recurrence-free survival (RFS). The reasons for the discrepant findings with respect of overall survival in the 3 trials have been unclear.
(more…)